<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">577</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2023-17-4-K703</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Predictors of reduced quality of life in patients with systemic sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Предикторы снижения качества жизни пациентов с системной склеродермией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7410-9784</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimenko</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Клименко</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ekaterina Pavlovna Mikheeva</p><p>1 Ostrovityanova St., Moscow 117997</p></bio><bio xml:lang="ru"><p>Екатерина Павловна Михеева</p><p>117997 Москва, ул. Островитянова, 1</p></bio><email>katherina.mikheeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-4517-8435</contrib-id><name-alternatives><name xml:lang="en"><surname>Mikheeva</surname><given-names>E. P.</given-names></name><name xml:lang="ru"><surname>Михеева</surname><given-names>Е. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> 1 Ostrovityanova St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, ул. Островитянова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4669-1006</contrib-id><name-alternatives><name xml:lang="en"><surname>Shostak</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Шостак</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> 1 Ostrovityanova St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, ул. Островитянова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2023</year></pub-date><volume>17</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>41</lpage><history><date date-type="received" iso-8601-date="2024-02-29"><day>29</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-02-29"><day>29</day><month>02</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Klimenko A.A., Mikheeva E.P., Shostak N.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Клименко А.А., Михеева Е.П., Шостак Н.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Klimenko A.A., Mikheeva E.P., Shostak N.A.</copyright-holder><copyright-holder xml:lang="ru">Клименко А.А., Михеева Е.П., Шостак Н.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/577">https://klinitsist.abvpress.ru/Klin/article/view/577</self-uri><abstract xml:lang="en"><p><bold>Aim</bold>. To study the predictors of a decrease in the quality of life of patients with Systemic Sclerosis (SSc) in the Russian population.</p><p><bold>Materials and methods</bold>. The study included 60 patients with a reliable diagnosis of SSc: 58 women and 2 men. The average age of the respondents was 61 ± 12.8 years. 29 patients had a P-limited form of SSc, 29 also had a diffuse form, and 2 had a form of systemic scleroderma without scleroderma. The results of clinical, laboratory and instrumental examinations were evaluated, as well as data obtained using the following questionnaires: quality of life assessments The Short Form-36 (SF-36), physical and mental components of health, the modified British Medical Research Council dyspnea scale (mMRC), a visual analog scale for assessing the severity of fatigue. The relationship of clinical manifestations and complications of the disease with the quality of life of patients has been determined.</p><p><bold>Results</bold>. The mean values of SF-36 (physical component) and SF-36 (mental component) in the examined patients were 36.08 ± 8.84 and 31.51 ± 12.7. Factors associated with poor quality of life in the physical component are the severity of shortness of breath (p &lt; 0.001) and the presence of subcutaneous calcifications (p &lt; 0.05), in the mental component – weakness (p &lt; 0.001).</p><p><bold>Conclusion</bold>. The quality of life of patients with SSc is reduced in both physical and mental components. The severity of shortness of breath, the presence of subcutaneous calcifications and weakness are the main predictors of a decrease in quality of life.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования</bold> – изучение предикторов снижения качества жизни пациентов с системной склеродермией (ССД) в российской популяции.</p><p><bold>Материалы и методы</bold>. В исследование включены 60 пациентов с достоверным диагнозом ССД: 58 женщин и 2 мужчин. Средний возраст респондентов составил 61 ± 12,8 года. Лимитированную форму ССД имели 29 пациентов, диффузную – также 29, форму ССД без склеродермы – 2. Оценены результаты клинико-лабораторного и инструментального обследований, а также данные, полученные с помощью следующих опросников: оценки качества жизни The Short Form-36 (SF-36), физического и ментального компонента здоровья, Британского медицинского исследовательского совета для оценки тяжести одышки (The Modified Medical Research Council Dyspnea Scale, mMRC), визуальной аналоговой шкалы для оценки выраженности слабости. Определена связь клинических проявлений, осложнений заболевания с качеством жизни пациентов.</p><p><bold>Результаты</bold>. Среднее значение SF-36 (физический компонент) и SF-36 (ментальный компонент) у обследуемых пациентов составило 36,08 ± 8,84 и 31,51 ± 12,7. Факторы, ассоциированные с низким качеством жизни по физическому компоненту – степень выраженности одышки (p &lt; 0,001) и наличие подкожных кальцинатов (p &lt; 0,05), по ментальному компоненту – слабость (p &lt; 0,001).</p><p><bold>Заключение</bold>. Качество жизни пациентов с ССД снижено и по физическому, и по ментальному компоненту. Степень выраженности одышки, наличие подкожных кальцинатов и слабость – основные предикторы снижения качества жизни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>systemic sclerosis</kwd><kwd>quality of life</kwd><kwd>dyspnea</kwd><kwd>calcinosis</kwd><kwd>fatigue</kwd><kwd>Raynauds phenomenon</kwd><kwd>physical component of health</kwd><kwd>mental component of health</kwd><kwd>predictors</kwd><kwd>SF-36 quality of life assessment questionnaire</kwd><kwd>risk factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>системная склеродермия</kwd><kwd>качество жизни</kwd><kwd>одышка</kwd><kwd>слабость</kwd><kwd>подкожные кальцинаты</kwd><kwd>феномен Рейно</kwd><kwd>физический компонент здоровья</kwd><kwd>ментальный компонент здоровья</kwd><kwd>предикторы</kwd><kwd>анкета оценки качества жизни SF-36</kwd><kwd>факторы риска</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Park E.H., Strand V., Oh Y. et al. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arthritis Res Ther 2019;21(1):61. DOI: 10.1186/s13075-019-1842-x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hromadkova L., Soukup T., Vlcek J. Quality of life and drug compliance: their interrelationship in rheumatic patients. J Eval Clin Pract 2015;21(5):919–24. DOI: 10.1111/jep.12399</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Abouyahya I., Liem S.I.E., Amoura Z. et al. Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. Clin Exp Rheumatol 2022;40(5):66–70. DOI: 10.55563/clinexprheumatol/x5aras</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Frantz C., Avouac J., Distler O. et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum 2016;46(1):115–23. DOI: 10.1016/j.semarthrit.2016.02.005</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Van Leeuwen N.M., Ciaffi J., Liem S.I.E. et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford) 2021;60(8): 3646–55. DOI: 10.1093/rheumatology/keaa827</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Valenzuela A., Baron M., Rodriguez-Reyna T.S. et al. Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Semin Arthritis Rheum 2020;50(5):891–6. DOI:10.1016/j.semarthrit.2020.06.007</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Murphy S.L., Kratz A.L., Whibley D. et al. Fatigue and Its Association With Social Participation, Functioning, and Quality of Life in Systemic Sclerosis. Arthritis Care Res (Hoboken) 2021;73(3):415–22. DOI: 10.1002/acr.24122</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fallahi P., Ruffilli I., Giuggioli D. et al. Associations between Systemic Sclerosis and Thyroid Diseases. Front Endocrinol (Lausanne) 2017;8:266. DOI: 10.3389/fendo.2017.00266</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hax V., Gasparin A.A., Schneider L. et al. Vitamin D and Cytokine Profiles in Patients With Systemic Sclerosis. J Clin Rheumatol 2020;26(7):289–94. DOI: 10.1097/RHU.0000000000001112</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Preis E., Franz K., Siegert E. et al. The impact of malnutrition on quality of life in patients with systemic sclerosis. Eur J Clin Nutr 2018;72(4):504–10. DOI: 10.1038/s41430-018-0116-z</mixed-citation></ref></ref-list></back></article>
